OncoMatch

OncoMatch/Clinical Trials/NCT06481735

TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL

Is NCT06481735 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell and Fludarabine for acute lymphocytic leukemia.

Phase 1/2RecruitingChinese PLA General HospitalNCT06481735Data as of Jun 2026Location: China

Treatment: TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell · Fludarabine · CyclophosphamideThe safety and efficacy of the chimeric antigen receptor (CAR)-T, a CD19-targeting, TRAC and Power3 (SPPL3) double gene deleted allogeneic CAR-T cell product, are undergoing rigorous evaluation in non-Hodgkin's lymphoma (NHL) subjects from the ATHENA trial (NCT06014073). Unexpectedly, expansion of the initial residual CD3-positive CAR T from products were measured in patients' peripheral blood (PB) without exception. Accompanying with host immune reconstitution and appearance of the detectable B cells, the CD3-positive allogenic CAR T cells exhibited a compelling amplification advantage over CD3-negative CAR T cells. The amplification of CD3-positive CAR T cell population dynamically suppressed host B cell recovery, and presumably surveilled the recurrence or progression of tumors, but did not induce typical Graft-versus-host-disease (GvHD). Additionally, a series of in vitro experiments illustrated that the human leukocyte antigen (HLA)-mismatched fratricide between host T cells and TCR-reserved Power3 (SPPL3)-deleted allogenic CAR T cells was markedly slashed, which in combination with investigators' observed clinical safety data supported the notion that only genomic deletion of Power3 (SPPL3) gene in allo-CAR T cells is sufficient to overcome GvHD and host T cell-mediated rejection response. In this study, investigators will disable the Power3 (SPPL3) gene of T cells from healthy donors to prepare CAR T cells. This approach harnesses the tonic signaling of CAR T cells, resulting in enhanced persistence and improved response to treatment. The purpose of this study is to evaluate the safety and efficacy of allogeneic Power3 (SPPL3) knock-out CD19 CAR-T in B-cell acute lymphoblastic leukaemia (B-ALL).

Check if I qualify

Extracted eligibility criteria

Treatments studied

Chemotherapy

FludarabineCyclophosphamide

Other

TCR reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T cell

Cancer type

Acute Lymphoblastic Leukemia

Biomarker criteria

Required: CD19 positive

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Demographics

Ages 16–70

Prior therapy

Must have received: chemotherapy — induction

relapsed or refractory disease as defined by not achieving an initial CR after 2 cycles of a standard chemotherapy regimen (primary refractory) or relapse after achieving CR

Cannot have received: immunocellular therapy

Patients who received any immunocellular or HSCT therapy within 3 months before enrollment

Cannot have received: hematopoietic stem cell transplant

Patients who received any immunocellular or HSCT therapy within 3 months before enrollment

Cannot have received: anti-leukemic therapy

Use of previous anti-leukemic therapy within 5 half-lives prior to allogeneic Power3 (SPPL3) knock-out CD19 CAR-T administration

Cannot have received: radioimmunotherapy

Exception: except prophylaxis of CNS involvement

Radioimmunotherapy, radiotherapy, within 8 weeks (except prophylaxis of CNS involvement) before Inclusion

Cannot have received: radiotherapy

Exception: except prophylaxis of CNS involvement

Radioimmunotherapy, radiotherapy, within 8 weeks (except prophylaxis of CNS involvement) before Inclusion

Lab requirements

Blood counts

Coagulation: INR ≤ 1.5 ULN, APTT ≤ 1.5 ULN

Kidney function

Serum creatinine ≤ 1.5 ULN or creatinine clearance ≥ 60 mL/min

Liver function

ALT/AST ≤ 3 ULN; Total bilirubin ≤ 1.5 ULN, except in subjects with Gilbert's syndrome

Cardiac function

Ejection fraction ≥ 50%, no evidence of pericardial effusion by ECHO, no clinically significant ECG findings

Adequate renal, hepatic, pulmonary and cardiac function defined as: Serum creatinine ≤1.5 ULN or creatinine clearance ≥ 60 mL/min; ALT/AST ≤ 3 ULN; Total bilirubin ≤ 1.5 ULN, except in subjects with Gilbert's syndrome; Cardiac ejection fraction ≥ 50%, no evidence of pericardial effusion as determined by ECHO, and no clinically significant ECG findings; Coagulation: INR ≤ 1.5 ULN, APTT ≤ 1.5 ULN; Baseline oxygen saturation >91% on room air.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06481735 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior immunocellular therapy, hematopoietic stem cell transplant, anti-leukemic therapy disqualifies patients from enrollment.

Does this trial require CD19?

Yes, CD19 positive is a required biomarker for enrollment.

Is there an age limit?

Yes. Patients must be 70 years or younger and at least 16 years old.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify